ACT now. ACT together to accelerate the end of the COVID-19 crisis.

ACT-Accelerator Facilitation Council

Co-Chairs Report on Emerging Issues

WHO MEMBER STATES BRIEFING

07 JULY 202
Agenda items today

1. Opening remarks
   Bruce Aylward, ACT-A/WHO

2. Council updates, ACT-A achievements & needs
   Professor Olive Shisana, South Africa

3. ACT-A independent evaluation
   Ambassador John-Arne Røttingen, Norway

4. Q&A
Opening remarks

Bruce Aylward
Global COVID-19 Situation – escalating cases

Cases and Deaths Reported to WHO as of 6 July 2022

- Last week New cases: > 5.1 million
- Last week new deaths: 9327
- Cumulative cases: > 548 million
- Cumulative deaths: > 6.34 million
Change COVID-19 cases & deaths by WHO region
Week 26 (03 Jul to 27 Jun) compared to Week 25 (26 Jun to 20 Jun)

<table>
<thead>
<tr>
<th>WHO Region</th>
<th>New cases in the last 7 days (%)</th>
<th>Change in new cases in last 7 days *</th>
<th>Cumulative cases (%)</th>
<th>New deaths in last 7 days (%)</th>
<th>Change in new deaths in last 7 days *</th>
<th>Cumulative deaths (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Europe</td>
<td>2,629,734 (51.4%)</td>
<td>24.1%</td>
<td>229,151,769 (41.9%)</td>
<td>2,592 (27.79%)</td>
<td>-3.9%</td>
<td>2,028,332 (32.0%)</td>
</tr>
<tr>
<td>Americas</td>
<td>1,388,644 (27.1%)</td>
<td>1.2%</td>
<td>163,465,247 (29.9%)</td>
<td>4,607 (49.39%)</td>
<td>10.6%</td>
<td>2,763,502 (43.6%)</td>
</tr>
<tr>
<td>Western Pacific</td>
<td>827,117 (16.2%)</td>
<td>3.7%</td>
<td>64,433,670 (11.8%)</td>
<td>1,526 (16.36%)</td>
<td>-11.5%</td>
<td>238,904 (3.8%)</td>
</tr>
<tr>
<td>South-East Asia</td>
<td>157,080 (3.1%)</td>
<td>19.9%</td>
<td>58,628,247 (10.7%)</td>
<td>364 (3.90%)</td>
<td>15.9%</td>
<td>790,178 (12.5%)</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>97,561 (1.9%)</td>
<td>30.8%</td>
<td>22,046,436 (4.0%)</td>
<td>112 (1.20%)</td>
<td>34.9%</td>
<td>343,597 (5.4%)</td>
</tr>
<tr>
<td>Africa</td>
<td>18,766 (0.4%)</td>
<td>-32.3%</td>
<td>9,134,504 (1.7%)</td>
<td>126 (1.35%)</td>
<td>-46.2%</td>
<td>173,620 (2.7%)</td>
</tr>
<tr>
<td>Global</td>
<td>5,118,902 (100%)</td>
<td>13.2%</td>
<td>546,860,637 (100%)</td>
<td>9,327 (100%)</td>
<td>1.2%</td>
<td>6,338,146 (100%)</td>
</tr>
</tbody>
</table>
ACT-Accelerator going forward

Strategic Plan runs to October – a ‘transition plan’ will adjust our ways of working for the period Oct 2022 through Mar 2023

Ensure ongoing implementation:

- continue ACT-A agencies support to countries
- continue work towards equitable access (esp. delivery)
- support countries move to longer term COVID-19 control

Maintain readiness – keep “warm” essential functions to be reactivated for COVID-19 resurgences

Future countermeasures platform to be developed in parallel
Our ACT-A Facilitation Council Co-Chair leads

**Professor Olive Shisana, Co-Chair ACT-A Council**
Social Policy Special Adviser to H.E. the President of South Africa

**Dr John-Arne Røttingen, Co-Chair ACT-A Council & Chair FinRMWG**
Ambassador for Global Health, Ministry of Foreign Affairs, Norway
Council updates, ACT-A achievements and needs

Professor Olive Shisana
The Facilitation Council provides high-level advice, guidance & leadership to facilitate the work of the ACT-Accelerator
ACT-Accelerator | 4 Pillars supported by a Member State-led Council for development of and equitable access to COVID-19 tools

**Vaccines (COVAX)**

**Therapeutics**

**Diagnostics**

**ACT-A Pillars & Delivery Partners**

**Political support & advocacy**

**ACT-A Facilitation Council Co-Chaired by**

- Financing & Resource Mobilization
- Tracking Accelerating
- Vaccine Manufacturing
- Tx & Dx Working Group

**Working groups**
Facilitation Council Working Groups

Set up to **structure and drive** the Facilitation Council’s work to provide **high-level political leadership** and enabling advice on global advocacy and resource mobilization.

<table>
<thead>
<tr>
<th>Working Group</th>
<th>Description</th>
<th>Chair</th>
<th>Co-Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tracking &amp; Accelerating Progress</td>
<td>Promoting the global targets for vaccines, therapeutics, diagnostics &amp; PPE.</td>
<td></td>
<td>Indonesia &amp; USA</td>
</tr>
<tr>
<td>Financial &amp; Resource Mobilization</td>
<td>Supporting call for higher income countries to contribute a “fair share” of ACT-A funding needs.</td>
<td>Co-Chairs:</td>
<td>Norway</td>
</tr>
<tr>
<td>Vaccine Manufacturing (delivered end-2021)</td>
<td>Enhance vaccine supply to COVAX, from supply chain to developing country production capacities.</td>
<td>Co-Chairs:</td>
<td>South Africa &amp; Germany</td>
</tr>
<tr>
<td>Diagnostics &amp; Therapeutics</td>
<td>Assessing current &amp; future barriers to production, demand &amp; access to COVID therapeutics &amp; tests.</td>
<td>Co-Chairs:</td>
<td>South Africa &amp; UK</td>
</tr>
</tbody>
</table>

Set up to structure and drive the Facilitation Council’s work to provide high-level political leadership and enabling advice on global advocacy and resource mobilization.
ACT-A Diagnostics & Therapeutics Working Group - update

- **Objective**: assess barriers to production, demand & access to COVID-19 Tx & Dx; recommendations to address barriers

- **Working Group launched**: May 16 - three meetings to date

- **Report**: by Sep 2022; share with Member States, G20, G7, etc
Tracking & Accelerating Progress Working Group – update & plans

I. Political outreach to accelerate COVID targets
   - political support to CoVDP priority countries

II. CSO roundtable
    - engagement to accelerate progress

III. Working Group Statement & media briefing
    - actions to speed access & end pandemic
Finance & RM Working Group - update

Resource mobilization campaign for G7 & G20

Coordinated diplomatic outreach to selected HICs

Consultation on highest priority financing needs

Commitment Tracker covering the two ACT-A budget cycles (2020/21 and 2021/22)

Financing Framework released 9 Feb 2022
**ACT-A achievements at July 2022**

**Vaccines**
Total of 3.7B vaccine doses secured through COVAX (1.56B vaccines delivered\(^1\))
>US$ 1.6B to support vaccine delivery in 124 low & middle income-countries.

**Tests**
US$ 972m awarded to countries for tests.\(^2\)
Over **951m tests delivered** by ACT-A\(^1\)

**Treatment**
**US$ 184m awarded** to countries for therapeutics & hospital equipment.\(^2\)
In addition, US$ 9m worth of COVID-19 **medicines procured** (US$ 7.9m delivered)

**Oxygen**
**US$ 560m awarded to countries for medical oxygen**\(^2\)
In addition, US$ 284m worth of oxygen supplies procured (US$ 187m delivered)

**PPE**
**US$ 767m awarded to countries for PPE.**\(^2\)
In addition, S$ 565m worth of PPE procured (US$ 463m delivered)

\(^1\)As of July 1, 2022, GCAT: [www.covid19globaltracker.org](http://www.covid19globaltracker.org)
\(^2\)As of end Q1 2022: [ACT-Accelerator: Quarterly Update Q1: 1 January – 31 March 2022](http://www.who.int)
Daily COVID-19 testing target: 100/100k pop/day; HICs rate 55x LICs rate

Dramatic testing declines everywhere hinder surveillance & timely detection of Variants

Since April, testing rates have almost halved in all income groups

Low testing rates of 4 & 22 per day/100k in LICs & LMICs are in substantial part the result of funding gaps

Low testing is an obstacle to roll out of new oral antivirals
COVID-19 vaccination needs: primary coverage only 14.8% in LICs
**ACT-A current budget:** US$ 5.6B committed, US$ 11.2B funding gap

**ACT-A contributions since October 30, 2021**

- United States of America 9.9%
- United Kingdom 13.3%
- Europe 22.7%
- Other philanthropic and private sector contributions 14.1%
- Austria 0.1%
- Belgium 0.3%
- Brazil 1.5%
- Canada 3.9%
- China 0.3%
- Denmark 0.2%
- France 4.6%
- Germany 10.5%
- Belgium 0.3%
- UNICEF National Committees 0.9%
- Netherlands 1.5%
- UNICEF 1.1%
- Other philanthropic and private sector contributions 1.4%
- Switzerland 0.1%
- African Union 0.1%
- Luxembourg 0.1%
- Finland 0.1%
- BlackRock Foundation 0.1%
- Iceland 0.1%
- Austria 0.1%
- Others 0.1%

**ACT-A 2021-22 budget**

- US$ 5.6 billion

**ACT-A funding gap since October 30, 2021 (US$ Billion)**

- Vaccines: 6.0
- Therapeutics: 2.5
- Diagnostics: 4.7
- HSRC: 3.7
- Pending allocation: 0.1
- Funding Gap: 11.2

**Note:** all financial commitments can be accessed at [https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker](https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker).
Funding since end-April | tests & treatments severely underfinanced

New funding since end-April 2022

Tests: +US$ 0.06B, 1.3% of the ask

Therapeutics: + US$ 0.05B, 2% of the ask

Vaccines Delivery: no add’l funding, still needs US$ 0.5B (US$ 0.3B to Unicef and US$ 0.2B to WHO)
Most urgently ACT-A financing needs – US$5.4 billion

- **Vaccines & Tests R&D** to ensure tools evolve ahead of virus

- **PPE, tests & treatments**, incl. novel antivirals, to protect workers, detect new variants, prevent severe disease, save lives

- **In-country delivery** incl. shots into arms\(^1\); roll out new antivirals

- In addition, **contingent financing** for Pandemic Vaccine Pool & Tx

\(^1\) including US$ 200 million for WHO & US$ 300 million for UNICEF for vaccine delivery
ACT-A Facilitation Council: status & next steps

The **most recent Facilitation Council was held on July 6th**

**Key discussion points:**
- escalating status of the COVID-19 pandemic
- waning political momentum in some areas to accelerate uptake of COVID-19 tools
- ACT-A’s work on the transition to long-term COVID-19 control

**Next Council:** plan to hold **Council transition meeting in end-Sept/early-Oct**

**A 6-month transition arrangement** will be put in place to ensure ongoing accountability & other essential functions as implementation continues into 2023.
ACT-A Independent Evaluation

Ambassador John-Arne Røttingen
ACT-A Independent Evaluation – WHO WGPR statement

“The WGPR noted the intention of the current co-chairs of ACT-A to initiate an independent evaluation of the platform and its successes and challenges, and noted that this was consistent with calls from many Member States for such an evaluation, and that it may be beneficial to share the results of that evaluation with Member States through the Health Assembly in due course.”
ACT-A Independent Evaluation

Approach

• ACT-A Facilitation Council will commission an independent, timely evaluation of ACT-A and its activities, identifying lessons learnt to inform a future global pandemic preparedness agenda

• Performed by an independent evaluation service provider

• A multi-pronged approach includes document review, survey(s) and key informant interviews

• Qualitative and quantitative

• Member States’ engagement and input will be very much appreciated
ACT-A Independent Evaluation Reference Group

• The reference group **co-designs, co-leads** and provides **supervision** to the evaluation

• Countries **chosen** based on expression of interest and level of engagement of Council members; CSOs nominated by the ACT-A CSO platform and PAN

• **6 countries** in addition to Co-Chairs Norway & South Africa: Brazil, Canada, Germany, India, Sweden, Nigeria

• **4 civil society organization** representatives: Pandemic Action Network; 3 representatives of ACT-A CSO Platform (led by WACI Health, STOP AIDS, Global Fund Advocates Network)
ACT-A Independent Evaluation: objectives and deliverables

Objectives

Lessons learnt and way forward:
- mandate
- set-up and structure
- achievement of its objectives & commitments
- resource mobilisation and financing
- gaps and missed opportunities
- way forward

Deliverables

Inception report reviewed by Reference Group

Evaluation report, including context and background; presentation of findings, conclusions and recommendations, reviewed by the Reference Group

Slide deck for dissemination
Timeline & milestones of the ACT-A independent evaluation

16 June 2022
Launch of Terms of Reference and Request for Proposals

20 June 2022
Deadline for submitting questions of clarification to Norad

22 June 2022
Response from Norad to possible questions of clarifications to all bidders

6 July 2022
Deadline for submission of proposals

20 July 2022
Draft inception report

25 July 2022
Final inception report

7 July 2022
Selection and contracting of Evaluation Service provider

Aug 2022

Sept 2022

Oct 2022

30 September 2022
Draft evaluation report

14 October 2022
Final evaluation report

2022
How Member States and other stakeholders can get involved in the evaluation

The inputs & perspectives of all stakeholders are highly valued

Please provide contact emails, names & affiliations by July 20:

Free unsolicited submissions to the evaluation are welcome up to Aug 15 on the theme: Please tell us what elements of the ACT-A experience you would like to see replicated or NOT replicated in the event of a future pandemic and what preparedness mode capacities need to be sustained (with name & contact email – see below)

Information on the evaluation, including further guidance on how to submit inputs will be posted on the ACT-A website next week:
https://www.act-a.org/evaluation
• Do you have any questions related to the operations of ACT-A and its priorities?

• What are in your view the key priorities for ACT-A in the global COVID-19 response in the coming months?

• Do you have any questions related to the independent evaluation?

• What should be the main informants & sources of information the evaluators use?
ACTaccelerator
ACCESS TO COVID-19 TOOLS